Press release
Hypertension Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hypertension Treatment Landscape @ Hypertension Pipeline Outlook [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hypertension Pipeline Report
* In August 2025, Keros Therapeutics Inc . announced a study of KER-012 in combination with background therapy in participants with PAH of World Health Organization (WHO) Group 1, functional class II-III. Participants will be randomly assigned in a 2:2:2:3 ratio to receive KER-012 (Dose A), KER-012 (Dose B), KER-012 (Dose C), or placebo by subcutaneous injection (SC) every 4 weeks for a period of 24 weeks in the placebo-controlled treatment period of the study while on background therapy.
* In August 2025, Actelion organized a study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=) 2 to less than () 18 years of age with Pulmonary Arterial Hypertension (PAH), by investigating the PK of selexipag and its active metabolite ACT-333679 in this population.
* DelveInsight's Hypertension pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Hypertension treatment.
* The leading Hypertension Companies such as Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
* Promising Hypertension Pipeline Therapies such as Ramipril and hydrochlorothiazide, Liraglutide , Nebivolol, Metoprolol XL, Aliskiren and HCTZ, Bunazosin, Doxazosin, Valsartin, losartan potassium and others.
Discover groundbreaking developments in Hypertension Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Hypertension Ongoing Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hypertension Emerging Drugs Profile
* Seralutinib: Gossamer Bio
Seralutinib, developed by Gossamer Bio, is an inhaled medication designed to treat pulmonary arterial hypertension (PAH). It functions as an antagonist of several receptors, including platelet-derived growth factor receptors (PDGFR and PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT. This multi-target approach aims to mitigate the inflammatory and proliferative pathways that contribute to pulmonary vascular remodeling associated with PAH. Currently, the drug is in the Phase III stage of its development for the treatment of Pulmonary Arterial Hypertension.
* AD-209: Addpharma Inc.
AD-209 is an investigational drug developed by Addpharma Inc., primarily targeting hypertension. It is part of a broader pipeline that includes various innovative medicines aimed at treating multiple conditions, including hyperlipidemia and diabetes. Currently, the drug is in the Phase III stage of its development for the treatment of Hypertension.
* Zilebesiran: Alnylam Therapeutics
Zilebesiran is an investigational RNA interference (RNAi) therapeutic developed by Alnylam Therapeutics, specifically targeting hypertension. It is designed to inhibit the synthesis of angiotensinogen (AGT), a key precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a crucial role in blood pressure regulation. Zilebesiran works by utilizing RNAi technology to selectively reduce the production of AGT in the liver. This reduction leads to decreased levels of angiotensin II, a potent vasoconstrictor that contributes to elevated blood pressure. By lowering AGT synthesis, zilebesiran aims to achieve sustained reductions in blood pressure over time. Currently, the drug is in the Phase II stage of development to treat Hypertension.
* LAM-001: ORPHAI THERAPEUTICS
LAM-001 is an investigational inhaled formulation of sirolimus (also known as rapamycin) developed by OrphAI Therapeutics. It is designed specifically for the treatment of pulmonary hypertension (PH) and bronchiolitis obliterans syndrome (BOS), conditions that can significantly impact lung function and patient quality of life. Currently, the drug is in the Phase II stage of development to treat Pulmonary Hypertension.
* HS135: 35Pharma Inc.
HS135 is an investigational drug developed by 35Pharma Inc., focusing on the treatment of pulmonary hypertension (PH) and related cardiometabolic diseases. It is a multi-specific receptor ectodomain ligand trap designed to neutralize activins and growth differentiation factors (GDFs), which are validated drivers of these conditions. HS135 functions as a ligand trap that specifically targets and inhibits the activity of activins and GDFs, particularly activin A and GDF-8. By doing so, it aims to rebalance the signaling pathways involved in various pathologies associated with pulmonary hypertension and obesity-related heart failure. Currently, the drug is in the Phase I stage of development to treat Pulmonary Arterial Hypertension.
The Hypertension Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Hypertension with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertension Treatment.
* Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypertension market
Stay informed about the Hypertension pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hypertension Unmet Needs [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hypertension Companies
Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Hypertension Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Transform your understanding of the Hypertension Pipeline! See the latest progress in drug development and clinical research @ Hypertension Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hypertension Pipeline Report
* Coverage- Global
* Hypertension Companies- Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc, Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical and others.
* Hypertension Pipeline Therapies- Ramipril and hydrochlorothiazide, Liraglutide, Nebivolol, Metoprolol XL, Aliskiren and HCTZ, Bunazosin, Doxazosin, Valsartin, losartan potassium and others.
* Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Cardiovascular Diseases Research-Access the Full Hypertension Pipeline Analysis Today! @ Hypertension Drugs and Companies [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hypertension: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hypertension - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Seralutinib: Gossamer Bio
* Mid Stage Products (Phase II)
* Zilebesiran: Alnylam Therapeutics
* Early Stage Products (Phase I)
* HS135: 35Pharma Inc.
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Hypertension Key Companies
* Hypertension Key Products
* Hypertension- Unmet Needs
* Hypertension- Market Drivers and Barriers
* Hypertension- Future Perspectives and Conclusion
* Hypertension Analyst Views
* Hypertension Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypertension-pipeline-outlook-report-2025-key-80-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hypertension-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertension Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4148572 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Hypertension
Hypertension Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hypertension Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hypertension Pipeline Report
• DelveInsight's Hypertension…
Hypertension Drugs Market - Breaking the Pressure: Hypertension Drugs Redefining …
Newark, New Castle, USA: The "Hypertension Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypertension Drugs Market: https://www.growthplusreports.com/report/hypertension-drugs-market/8760
This latest report researches the industry structure, sales, revenue,…
Hypertension Management Devices Market: Rise in Prevalence of Resistant Hyperten …
Market Analysis and Insights of Hypertension Management Devices Market
Hypertension Management Devices Market to account USD 9.50 billion and growing at a CAGR of 7.27% by 2032. Although there are still numerous variations available, the major market players are currently developing and testing clinical versions of hypertension treatment devices. Due to the lack of available effective medications, these medical devices are being created with the primary goal of managing cardiovascular illnesses…
Anti-hypertension - Drug Pipeline Landscape, 2022
Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
Renal Hypertension: Diagnosis & Treatment
“Hypertension & Cardiovascular disease after Kidney Transplantation” is one of the workshops to be conducted by Dr. Hossein Tabriziani of Loma Linda University, USA under the session ‘Renal Hypertension’ at the meeting 2nd International Conference on Hypertension & Healthcare which is going to be held at Amsterdam, Netherlands during September 11-13, 2017.
High blood pressure is a leading cause of kidney disease and kidney failure ESRD (end stage renal disease). Hypertension…
